The findings of this study suggest that a distinct group of young patients with aggressive prostate cancer is frequently associated with TMPRSS2:ERG fusions, while exhibiting a lower likelihood of harboring mutations in other genes, such as AR, SPOP, and ASXL1 [35]. The gene discussed is AR; the disease is prostate carcinoma.